Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
By: Nasdaq / GlobeNewswire - 16 Aug 2019 | Back to overview list |
|
WALTHAM, Mass. and CRESTWOOD, Ky., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on August 12, 2019, the Company approved the grant of equity awards to three new employees with a grant date of August 12, 2019, as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to each employee's acceptance of employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 27,300 shares of Apellis common stock. The options have an exercise price of $26.83 per share, which is equal to the closing price of Apellis common stock on August 12, 2019. One-fourth of the shares underlying each employee option will vest on the one year anniversary of each employee’s date of hire and thereafter 1/48th of the shares underlying each employee option will vest monthly, such that the shares underlying the options granted to the employee will be fully vested on the fourth anniversary of each employee’s date of hire, subject to each employee’s continued employment with Apellis on such vesting dates. About Apellis Forward-Looking Statements CONTACT: Media Contact: Ryan Wade ryan.wade@apellis.com 781.209.6460 x8148 (office) 781.801.5206 (mobile) Investor Contact: Alex Kane akane@w2ogroup.com 212.301.7218 (office) 929.400.2691 (mobile) |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |